Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5980_Библиотеки_им_академика_М_И_Перельмана.pdf
376 Cocrystals in Pharmaceutical Sciences
25. Almansa, C., Frampton, C.S., Vela, J.M., Whitelock, S., Plata-Salaman, C.R.,
Cocrystals as a new approach to multimodal analgesia and the treatment of
pain. J. Pain Res., 12, 2679–2689, 2019.
26. Rigilin, S., Kunjal, K.K., ayyil, A.R., Shabaraya, R.A., FDA regulatory
implications for cocrystals and recent cocrystal patents. Int. J. Drug Regul.
A., 10, 3, 10–18, 2022.
27. Xia, M.Y., Zhu, B.Q., Wang, J.R., Yang, Z.E., Mei, X.F., Superior dissolution
behavior and bioavailability of pharmaceutical cocrystals and recent regula-
tory issues. ACS Med. Chem. Lett., 13, 1, 29–37, 2021.
28. Gadade, D.D. and Pekamwar, S.S., Pharmaceutical cocrystals: regulatory and
strategic aspects, design and development. Adv. Pharm. Bull., 6, 4, 479, 2016.
29. Stirk, A.J., Souza, F.E., Gerster, J., Mir, F.M., Karadeolian, A., Rey, A.W.,
Formation of pharmaceutical salts and cocrystals via vapour-assisted tum-
bling (VAT)–a solvent ecient process. Green Chem., 24, 4, 1505–1514,
2022.
30. Saraf, G.J., Burade, K., Gonjari, I., Hosmani, A., Pawar, A.A., A review on
advances in Pharmaceutical cocrystal preparation routes, intellectual prop-
erty perspective and regulatory aspects. Int. J. Curr. Pharm. Res., 14, 5, 4–12,
2022.
31. Jafari, M.K., Padrela, L., Walker, G.M., Croker, D.M., Creating cocrystals:
A review of pharmaceutical cocrystal preparation routes and applications.
Cryst. Growth Des., 18, 10, 6370–6387, 2018.
32. European of Medicines cocrystals, of Agency. active Reection substances in
paper medicinal on the products, Reection paper on the use of cocrystals of
active substances in medicinal products (europa.eu), 2014.
33. FDA, Guidance for Industry Regulatory Classication of Pharmaceutical
Cocrystals, 2013, https://www.fda.gov/.
34. FDA, Guidance for Industry ANDAs : Pharmaceutical Solid Polymorphism,
Guidance for Industry (fda.gov), 10
th
July 2007.
35. ICH, Organisation of the common technical document for the registration
of pharmaceuticals for human use M4, vol. 5, ICH Ocial web site : ICH, pp.
1–44, 2004.
36. Kittel, C., Introduction to Solid State Physics, 8th Edition, Wiley, United
States, 2004.
37. Gad, S.C., Preclinical Development Handbook: ADME and Biopharmaceutical
Properties, Preclinical Development Handbook, Wiley Online Books, United
States, 2008.
38. ICH, ICH Q11: Development and manufacture of drug substances-
chemical and biotechnological/biological entities, vol. 1(3), ICH Ocial web
site: ICH, p. 30, 2012.
39. Committee for Medicinal Products for Human Use, Guideline on Excipients
in the Dossier for Application for Marketing Authorisation of a Medicinal
Product, 2007, guideline-excipients-dossier-application-marketing-authori-
sation-medicinal-product-revision-2_en.pdf (europa.eu).
Patents & Regulatory Concerns of Cocrystals 377
40. Food and Drug Administration, Guidance for Industry Nonclinical Studies
for the Safety Evaluation of Pharmaceutical Excipients, FDA Guidance,
Nonclinical Studies for the Safety Evaluation of Pharmaceutical Excipients |
FDA, 2005.
41. Schultheiss, N. and Newman, A., Pharmaceutical Cocrystals and eir
Physicochemical Properties. Cryst. Growth Des., 9, 6, 2950–2967, 2009.
42. Lee, E.H., A practical guide to pharmaceutical polymorph screening & selec-
tion. Asian J. Pharm. Sci., 9, 4, 163–75, 2014.
43. Aston, J.G., Fink, H.L., Tooke, J.W., Ones, M.R., Melting Point Calorimeter
for Purity Determinations. Anal. Chem., 19, 218–221, 1947.
44. Guideline on the Investigation of Bioequivalence (europa.eu), 2010.
45. U. S. Food and Drug Administration, Waiver of In Vivo Bioavailability and
Bioequivalence Studies for Immediate Release Solid Oral Dosage Forms
Based on a Biopharmaceutics Classication System, 2017, https://www.fda.
gov/.
46. European Medicines Agency, Agomelatine oral tablet 25 mg product-specic
bioequivalence guidance (europa.eu), 2017.
47. L.R. and Gillivray, M., Cocrystals and Salts of Contrast Agents and Imaging,
US 2014/0004051A1, assigned to University of Iowa Research Foundation,
United States, 2014.
48. Lane, B.S. and Gu, C.H., Cocrystals, pharmaceutical compositions thereof,
and methods of treatment involving same, US 2022/0363661 A1, assigned to
Servier Pharmaceuticals LLC, United States, 2022.
49. Glick, G.D., Franchi, L., Santus, G., Methods and compositions for treating
conditions associated with an abnormal inammatory response, US10292951
B2, assigned to First wave Bio, Inc., United States, 2019.
50. Hornedo, N.R., Kuminek, G., Cavanagh, K.L., Cocrystals of Posaconazole,
Method of Making and Using Same, WO2021/022103 A1, assigned to e
Reagents of e University Of Michigan, Switzerland, 2021.
51. Reddy, R., Reddy, R.R., Dasari, Ramakrishna, M., Crystalline alfuzosin base,
US 2007/0100143 A1, assigned to Hetero Drugs Limited, United States, 2007.
52. P.L. Rafel, B.C. Rafael, L.B. Herrera, D.F. Lopez, Cocrystals Of Ubiquinol
And Composition Comprise em, WO2019/162429 A1, 2019.
53. Oracz, M. and Skoczen, P., Cocrystals of apremilast, EP3339292A1, assigned
to Zaklady Farmaceutyczne Polpharma SA, Europe, 2018.
54. Zaworotko, M.J., Shytle, R.D., Ong, T.T., Kavuru, P., Cantwell, N.R., Nguyen,
T., Smith, J.A., Lithium compositions, EP2688575B1, assigned to University
of South Florida, Europe, 2016.
55. Salaman, C.R.P., Cés, S.V., Tesson, N., Castano, M.T., Cocrystals of venlafax-
ine and celecoxib, EP 2 340 818 A1, assigned to Esteve Pharmaceuticals SA,
Europe, 2011.
56. Bak, A. and Ostovic, D., Sorbic Acid Analogue Cocrystals Patent, EP 2056798
A2, assigned to Amgen, Inc, Europe, 2009.
378 Cocrystals in Pharmaceutical Sciences
57. Brittain, H.G. and Felice, P.V., Intravenous Formulation with water soluble
cocrystals of Acetylsalicylic Acid and theanine, AU2013201664 B2, assigned
to eaprin Pharmaceuticals Inc, Australia, 2015.
58. David, G., Methods for preparing mixed phase cocrystals with activator,
JP2007516259A, assigned to Med Crystals Forms, LLC, Japan, 2007.
59. Parent, S.D., Schultheiss, N.C., Wu, Y., Bevill, M.J., Houston, T.L., Vlahova,
P., New form of rifaximin and uses thereof, NZ710780A, assigned to Slix
Pharmaceuticals Ltd, New Zealand, 2017.
60. Jianfeng, L., Guanghui, T., Zhen, W., Jin, S., Xiangrui, J., Zheng, L., Xiaojun,
Y., Zhu, X., Xianguo, Z., Weiliang, Z., Hualiang, J., Jingshan, S., e salt of
a kind of pyrazolo pyrimidinone compound, polymorph and pharmaceu-
tical composition, preparation method and application, CN102952138B,
Assigned to Topharman Shandong Co Ltd, China, 2016.
379
Index
π-π interactions, 45
6-mercaptopurine, 5, 6, 20
Abridged applications, 367
Active pharmaceutical ingredients
(APIs), 2, 29, 55, 293–294, 342
Agrochemical cocrystals, 30
Amino acid in cocrystal, 266
Amorphous drug structure, 304
Amorphous solid dispersions, 56
ANDA, 357, 362, 368–370
Andrographolide-salicylic acid
cocrystal, 317–318
Anticancer DDCs, 202
Anti-cancer drugs, 272–278
Antiretroviral, 7, 26
Antisolvent, 93, 95, 102, 103, 107
Antitubercular DDCs, 206
API crystal forms, 33
Aripiprazole, 141
Aromatic π-π stacking, 45
Articial neural network, 248
Azelnidipine, 141
Baicalein-caeine cocrystal, 315
Batch manufacturing, 237
Betti reaction, 125
Bioavailability, 1, 3–6, 14–16, 20–21,
26, 33, 232, 236, 243, 247, 248,
259, 263
Bioavailability enhancement, 312–316
Bioavailability enhancement
techniques, 33
Caeine, 7, 9, 12, 14
Cambridge crystallographic data
centre, 69
Cambridge structural database (CSD),
38
Cambridge structural database (CSD)
analysis, 57, 58, 69–72
Carbamazepine, 6, 7, 11, 12
Carbamazepine–saccharin cocrystals,
141
Catalyst stability, 30
Catechol, 140
Characterization methods, 295–297
Charge transfer interactions, 30
Chemical stability, 308–311
Chlordiazepoxide cocrystals, 126
Clinical trials, 321
CO
2
assisted spray drying, 106
Cocrystal challenges, 47
Cocrystal characterization, 46
Cocrystal design, 35
Cocrystal design principles, 293–294
Cocrystal dissolution, 33
Cocrystal formation mechanisms,
294–295
Cocrystal formation techniques, 47
Cocrystal libraries, 38
Cocrystal preparation techniques,
295–296
Cocrystal safety, 39
Cocrystal screening, 38
Cocrystal screening methods, 295
Cocrystal solubility, 33
Cocrystal therapeutics, 33
380 Index
Cocrystallization, 30, 330–335,
337–340, 343–345, 347–349
Cocrystals, 56, 231–244, 246, 247, 249,
250
Cocrystals based tablets, 330–333
Coformer, 56, 232, 240, 244, 247, 257,
259
Coformer selection, 35
Combination therapy, 9, 23, 26
Combination therapy approaches,
316–318
Combinatorial approaches, 40
Compactibility, 335
Compaction, 331–335, 338, 339, 342
Compressibility, 329–330, 332–333,
335
Computational methods, 55, 56, 62
Computational modeling, 322
Continuous manufacturing, 47, 231,
237, 238, 239, 240, 244
Controlled release, 8, 17, 22
Cooling crystallization, 93, 95, 101,
102, 111
COSMO-RS (conductor-like screening
model for real solvents) approach,
57, 58, 72–75
Crystal engineering, 2, 4, 5, 19–25, 44,
55, 56
Crystal lattice stability, 45
Crystal morphology, 44
Crystal packing, 36
Crystal structure prediction (CSP)
method, 57, 58, 76–78
Crystal symmetry, 44
Crystallization methods, 41
CTD, 358, 366–368
Curcumin, 5, 11, 31
DDCs, 189–192, 196–198, 200–206
Deformation, 332–335
Dierential scanning calorimetry
(DSC), 46, 57, 61, 123, 126
Dissolution rate, 260, 257, 258, 259
Dissolution rate improvement,
303–305
Dissolution rate studies, 46
Diuretics DDCs, 209
Drug absorption, 33
Drug bioavailability, 33
Drug degradation prevention,
314–315
Drug delivery, 1, 3, 17, 21, 33
Drug permeability, 33
Drug permeability enhancement,
314–315
Drug polymorphism, 33
Drug solubility parameters, 33
Drug stability, 29
Drug-drug cocrystal, 32, 279–281,
316–318
Drug-excipent interactions, 39
Efavirenz with nevirapine, 128
Efavirenz with zid-ovudine, 128
Elastic recovery, 332
EMA, 357–358, 362–369, 373
EMA regulations, 320–321
Endothermic peak, 127
Enhanced solubility, 5, 16, 21, 22
Entresto, 321
Environmental-friendly synthesis, 48
Epicatechin, 124
Ethenzamide, 143
European medicines agency (EMA), 2,
232, 235, 249
Exothermic peak, 127
Factors aecting solubility, 260–263
common-ion eect, 263
molecular size, 262
nature of solute and solvent, 260
particle size, 260
polarity, 262
polymorphism, 262
pressure, 261
temperature, 261
FDA guidelines, 319–320
Index 381
Field emission scanning electron
microscopy (FESEM), 46
FLEXCRYST, 72
Flowability, 333
Food additive applications, 30
Food encapsulation, 281–282
Formulation optimization, 37
Fourier transformation infrared
(FTIR), 46, 57, 61
Friedrich Wöhler, 3
Future directions, 246
Future perspectives, 322–323
Garbacz and Wesolowski, 126
Glutaric acid, 5, 7, 21, 23
Green chemistry, 248
Green chemistry in cocrystals, 48
Halogen bonding, 30
Hansen solubility parameters (HSPs), 37
Herbal bioactive, 267
Hetero-synthons, 57, 266, 264
High-throughput experimentation, 41
Hirshfeld surface (HS), 57, 58, 66–69
Hirshfeld surface analysis, 132
Homo-synthons, 57, 266
Hot-melt extrusion, 93, 95, 98, 107,
236, 241, 265–266
Hot-phase microscopy, 128
Hydrated cocrystals, 32
Hydrogen bond donors/acceptors, 45
Hydrogen bonding, 30
Hydrophobic drug stabilization, 48
Hydrophobic interactions, 33
Hygroscopicity, 331, 341–349
Hygroscopicity control, 303–304
ICH, 363–364, 367–368
Improved bioavailability, 5, 15, 16
Improved stability, 14–16
In silico screening, 38
Infrared spectroscopy, 123
Insulin, 8, 22
Interaction energy calculations, 43
Intermolecular forces, 294
Intermolecular interactions, 233
Ionic cocrystals, 140
Isoniazid-pyrazinamide cocrystal, 318
Isonicotinamide, 125
Kinetics of cocrystallization, 233, 234
Lattice energy calculations, 77
L-histidine, 140
Liquid assisted grinding, 41, 95, 97
Liquid-assisted grinding method, 60
Lorazepam cocrystals, 127
Machine learning, 246, 247
Manufacturing considerations, 320
Mechanical properties, 305–307, 330
Mechanochemical cocrystallization,
231, 240, 241
Mechanochemical method, 59
Mechanochemical synthesis, 47
Medicinal cocrystals, 48
Melting point, 33
Melting point modication, 302–303
Mercury, 58
Micro electron diraction (MicroED),
61
Molecular electrostatic potential
surface (MEPS) measurement,
57–58, 62–66
Molecular recognition, 35
Monoclinic crystal, 125
Multicomponent molecular cocrystals,
33
Multicomponent systems, 35
Nano-cocrystals, 318–319
Nateglinide, 125
NDA, 357, 370
Neat grinding, 95, 96, 97, 106
Neat grinding method, 59–60
Nitrofurantoin, 7, 22
Nonpolar solvent, 260, 262
NSAIDS DDCs, 199
382 Index
Nuclear magnetic resonance (NMR),
46, 123
Nutraceuticals, 9, 11, 12, 17
Optical properties, 306–307
ORTEP (Oak Ridge ermal Ellipsoid
Plot Program), 58
Particle size, 242, 243, 244, 245, 260
Patent, 214–217, 357, 361, 363, 370, 373
Patent protection, 47
Permeability, 264
Pharmaceutical cocrystals, 29, 56
Pharmaceutical combinatorial
libraries, 41
Pharmaceutical formulations, 29
Pharmaceutical industry, 232, 236,
242, 246, 250
Pharmaceutical patents, 47
Pharmacokinetic improvements,
312–316
Pharmacokinetics, 33
Physicochemical properties, 33,
302–307
Piperazine, 140
Piroxicam, 124
Plastic deformation, 332–334
Plasticity, 330–335, 338
Polar solvent, 260
Polymeric eect, 266–267
Polymorph control, 34
Polymorphic forms, 243
Polymorphism, 33
Porosity, 335
Powder x-ray diraction (PXRD), 57, 60
Powder XRD (PXRD), 46
Process analytical technology (PAT),
110–111, 237, 248
Pterostilbene, 5, 21
p-toluenesulfonic acid, 140
Quality, 357, 363, 366–369
Quality-by-design (QbD), 110–111,
233, 322
Regulatory, 357, 361–374
Regulatory challenges in cocrystals, 47
Regulatory classication, 47
Regulatory compliance, 235
Regulatory guidelines, 47
Regulatory requirements, 319–321
Resorcinol, 140
RS-ketoprofen, 124
Salt formation, 33
Salt-cocrystal continuum, 34
Scale-up, 231, 233, 234, 235, 236, 237,
241, 244, 245
Scale-up challenges, 322
Scanning electron microscopy (SEM),
57, 62, 123
Single crystal XRD (SCXRD), 44
Single-crystal X-ray Diraction
(SCXRD), 60, 123, 124
Slurry cocrystallization, 240
Slurry conversion, 100, 101
Slurry-based process, 59
Solid dispersion, 33
Solid-state analysis, 36, 295–297
Solid-state characterization
techniques, 57
Solid-state forms, 33
Solid-state NMR, 46
Solid-state nuclear magnetic
resonance, 123
Solubility, 329–330, 341, 342, 344
Solubility enhancement, 19, 20, 29,
303–305
Solubility predictions, 43
Solution cooling crystallization, 259
Solvent drop grinding, 259, 271
Solvent eects, 34
Solvent evaporation, 93–95, 99, 100,
103, 105
Solvent evaporation method, 59
Solvent selection, 37
Solvent vaporization technique, 259,
260, 277
Solvent-free techniques, 47
Index 383
Spray drying, 103, 231, 236, 237
Spray freeze-dried process, 237
Stability, 329–332, 334, 340–350
Stability enhancement, 6, 21
Stability improvement, 308–312
Static TGA, 128
Stoichiometry, 3, 13
Supramolecular chemistry, 2
Supramolecular engineering, 35
Supramolecular interactions, 39
Supramolecular synthons, 35, 43, 57,
259, 265, 266, 294
Tabletability, 8, 22, 330, 332–335,
336–341, 345
Targeted drug delivery, 318–319
Taste masking, 7, 22, 48
Tensile strength, 330, 332, 335–336,
338, 339, 341
Terahertz, 129
erapeutic eciency, 48
ermal analysis, 41
ermal gradient cocrystallization, 41
ermal stability, 36, 232, 247,
311–312
ermogravimetric analysis, 123, 127
ermogravimetry analysis (TGA),
57, 61
Tramadol-celecoxib cocrystal, 317
Trinitrotoluene, 125
Twin screw extruder, 96, 104, 105
United States Food and Drug
Administration (USFDA), 2,
57–358, 361–369, 373
X-ray crystallography, 44
X-ray diraction analysis, 296
X-ray photoelectron spectroscopy
(XPS), 61